Nervgen Pharma (NGEN) Cash from Discontinued Operations (2025 - 2026)
Nervgen Pharma's (NGEN) quarterly Cash from Discontinued Operations came in at -$6.0 million in Q1 2026, down 108.31% year-over-year from $72.0 million in Q1 2025, and down 108.31% quarter-over-quarter from -$2.9 million in Q1 2025.
Powered by 
Analysis
Nervgen Pharma (NGEN) Cash from Discontinued Operations (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Cash from Discontinued Operations for 2 consecutive years, with -$6.0 million the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Nervgen Pharma | 156.23 Mn | 156.23 Mn | - | - |